Lantern Pharma (NASDAQ: LTRN), an artificial intelligence-driven oncology company, announced it will host a webcast on Aug. 14, 2026, at 9 a.m. ET to discuss its second-quarter 2026 operating and financial results. President and CEO Panna Sharma, joined by members of the management team, will review the quarter ended June 30, 2026, and provide updates on upcoming milestones, clinical trials, and developments involving the company's RADR® and Open-Medicine AI platforms. A webcast replay will be available through the investor relations section of Lantern Pharma's website following the event.
This announcement comes as Lantern continues to leverage artificial intelligence and machine learning to accelerate the development of cancer therapies. The company's proprietary RADR® platform is central to its strategy, enabling the identification of patient populations most likely to benefit from its drug candidates. Lantern's clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound for hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial for never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. Additionally, LP-184 is being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern's wholly owned CNS-focused subsidiary.
A significant recent development is the commercial availability of withZeta.ai, Lantern's multi-agentic AI co-scientist platform, now offered as a subscription-based research platform for the global biomedical and drug development community. This represents a new revenue stream for the company and underscores its commitment to expanding beyond drug development into broader AI applications. Lantern also operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas.
The upcoming webcast is particularly important for investors and stakeholders as it will provide a comprehensive overview of the company's financial performance and strategic direction. With the integration of AI across its operations, Lantern is positioning itself at the forefront of precision oncology, potentially improving the efficiency and success rates of cancer drug development. The company's focus on both clinical advancement and commercial AI offerings suggests a dual-pronged growth strategy that could enhance long-term shareholder value.
As the biotech sector increasingly embraces AI, Lantern's progress will be closely watched. The webcast will offer insights into how the company plans to leverage its platforms to address unmet medical needs and drive future growth. For more information, visit the full press release at https://ibn.fm/l80kv. Additionally, the latest news and updates relating to LTRN are available in the company's newsroom at https://ibn.fm/LTRN.
